Sign In
Buy PSTV
$5.42
-0.0500 (-0.91%)
At Close: Jun 03, 2026
Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting
07:30am, Thursday, 04'th Dec 2025
Cohort 1 data from multiple dose ReSPECT- Leptomeningeal Metastases (LM) trial showed no dosage limiting toxicity
HOUSTON, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced plat
HOUSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceutica
Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
07:30am, Thursday, 20'th Nov 2025
HOUSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it ha
Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement
07:30am, Monday, 17'th Nov 2025
HOUSTON, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with
Leptomeningeal metastases disease session features novel treatments in the horizon, REYOBIQ™ and ReSPECT-LM, and future directions and needs Leptomeningeal metastases disease session features novel
Plus Therapeutics (PSTV) Reports Q3 Loss, Lags Revenue Estimates
07:46pm, Thursday, 30'th Oct 2025
Plus Therapeutics (PSTV) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.46 per share a year ago.
Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights
04:15pm, Thursday, 30'th Oct 2025
US market introduction of the CNSide® CSF diagnostics platform, with first national coverage agreement with UnitedHealthcare
Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch
07:30am, Tuesday, 21'st Oct 2025
Expands commercial readiness and diagnostic, manufacturing footprint Appoints new leadership in commercial strategy and technical operations HOUSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutic
5 Small Drug Stocks to Buy as the Industry Shows Some Recovery
12:01pm, Tuesday, 14'th Oct 2025
Innovation is at its peak in the Zacks Medical-Drugs industry. AKBA, IRWD, PYXS, CRDL and PSTV may prove to be good additions to one's portfolio.
These Penny Stocks are Soaring Today: DFLI, YCBD, PSTV
01:13pm, Monday, 29'th Sep 2025
The image featured for this article is © Canva: golubovy from Getty Images and Bigc Studio
HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it h
Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT
07:30am, Monday, 22'nd Sep 2025
Non-dilutive payment is part of $17.6 million award granted for the Company's leptomeningeal cancer targeted radiotherapeutic development program HOUSTON, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Plus Thera
Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory
07:30am, Thursday, 18'th Sep 2025
Certification critical to broad U.S. market release of the CNSide CSF Assay Platform CNSide now meets key federal and state regulatory requirements, including those set by the Centers for Medicare and
Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
04:15pm, Tuesday, 02'nd Sep 2025
HOUSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics wit
